Marianne Gex-Fabry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marianne Gex-Fabry has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chin Bin Eap
Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
2 shared publications - Gilles Bertschy
Department of Psychiatry and Mental Health, Strasbourg University Hospital, INSERM U1114, University of Strasbourg, F-67000 Strasbourg, France
2 shared publications Guido Bondolfi
From the *Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chêne-Bourg, Switzerland; and †Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Department of Psychiatry-CHUV, Cery Hospital, University of Lausanne, Prilly, Switzerland
2 shared publicationsJean-Michel Aubry
From the *Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chêne-Bourg, Switzerland; and †Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Department of Psychiatry-CHUV, Cery Hospital, University of Lausanne, Prilly, Switzerland
2 shared publicationsNicola Gervasoni
From the *Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chêne-Bourg, Switzerland; and †Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Department of Psychiatry-CHUV, Cery Hospital, University of Lausanne, Prilly, Switzerland
2 shared publicationsBeatrice Oneda
From the *Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chêne-Bourg, Switzerland; and †Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Department of Psychiatry-CHUV, Cery Hospital, University of Lausanne, Prilly, Switzerland
1 shared publication
Latest Publications
- 1 August 2008
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 30 (4) , 474-482
CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response
Paroxetine is characterized by large interindividual pharmacokinetic variability and heterogeneous response patterns. The present study investigates plasma concentration and therapeutic response to paroxetine for the influence of age, sex, and CYP2D6 and ABCB1 polymorphisms, the latter gene encoding for the permeability glycoprotein. Genotyping for CYP2D6 (alleles *3, *4, *5, *6, and *xN) and ABCB1 polymorphisms (61A>G, 2677G>T, and 3435C>T) was performed in 71 depressed patients who started 20 mg paroxetine per day and had plasma concentration measured after 2 weeks at a fixed dose. A dose increase to 30 mg per day was possible starting at week 2. For 63 patients, severity of depression (Montgomery-Åsberg Depression Rating Scale) was assessed at weeks 0, 2, and 4 and every 2 weeks thereafter until discontinuation. Persistent response was defined as 50% improvement from baseline score sustained from the first occurrence to study end point. Paroxetine concentration significantly differed between female and male patients (median, 28 versus 16 ng/mL; P = 0.001). Differences were not significant between CYP2D6 heterozygous and homozygous extensive metabolizers (median, 27 versus 22 ng/mL; P = 0.074) and between ABCB1 genotypes (P > 0.10). When considered in a multivariate model, CYP2D6 heterozygous extensive metabolizer phenotype (P = 0.062) and female gender (P = 0.001) predicted 1.3-fold and 1.6-fold higher paroxetine concentration, respectively, but fraction of explained variability was modest (21%). Frequency of persistent response at study end point did not significantly differ according to CYP2D6 heterozygous extensive metabolizer versus homozygous extensive metabolizer phenotype and ABCB1 polymorphisms in univariate analyses. After adjusting for age, sex, paroxetine concentration at week 2, and daily dose at study end point, ABCB1 genotype contributed to improving the model significantly for 61A>G (P = 0.043), but not 2677G>T (P = 0.068) and 3435C>T (P = 0.11). None of two poor metabolizers and four ultrarapid metabolizers showed persistent response to paroxetine. The hypothesis that permeability glycoprotein activity might be a relevant predictor of therapeutic response deserves to be further investigated while controlling for pharmacokinetic variability.
- 1 August 2008
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 30 (4) , 474-482
CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response
Paroxetine is characterized by large interindividual pharmacokinetic variability and heterogeneous response patterns. The present study investigates plasma concentration and therapeutic response to paroxetine for the influence of age, sex, and CYP2D6 and ABCB1 polymorphisms, the latter gene encoding for the permeability glycoprotein. Genotyping for CYP2D6 (alleles *3, *4, *5, *6, and *xN) and ABCB1 polymorphisms (61A>G, 2677G>T, and 3435C>T) was performed in 71 depressed patients who started 20 mg paroxetine per day and had plasma concentration measured after 2 weeks at a fixed dose. A dose increase to 30 mg per day was possible starting at week 2. For 63 patients, severity of depression (Montgomery-Åsberg Depression Rating Scale) was assessed at weeks 0, 2, and 4 and every 2 weeks thereafter until discontinuation. Persistent response was defined as 50% improvement from baseline score sustained from the first occurrence to study end point. Paroxetine concentration significantly differed between female and male patients (median, 28 versus 16 ng/mL; P = 0.001). Differences were not significant between CYP2D6 heterozygous and homozygous extensive metabolizers (median, 27 versus 22 ng/mL; P = 0.074) and between ABCB1 genotypes (P > 0.10). When considered in a multivariate model, CYP2D6 heterozygous extensive metabolizer phenotype (P = 0.062) and female gender (P = 0.001) predicted 1.3-fold and 1.6-fold higher paroxetine concentration, respectively, but fraction of explained variability was modest (21%). Frequency of persistent response at study end point did not significantly differ according to CYP2D6 heterozygous extensive metabolizer versus homozygous extensive metabolizer phenotype and ABCB1 polymorphisms in univariate analyses. After adjusting for age, sex, paroxetine concentration at week 2, and daily dose at study end point, ABCB1 genotype contributed to improving the model significantly for 61A>G (P = 0.043), but not 2677G>T (P = 0.068) and 3435C>T (P = 0.11). None of two poor metabolizers and four ultrarapid metabolizers showed persistent response to paroxetine. The hypothesis that permeability glycoprotein activity might be a relevant predictor of therapeutic response deserves to be further investigated while controlling for pharmacokinetic variability.
- 1 May 2007
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 31 (4) , 892-900
Time course of response to paroxetine: Influence of plasma level
- 1 May 2007
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 31 (4) , 892-900
Time course of response to paroxetine: Influence of plasma level